Business
Wegovy Pill Dominates GLP-1 Market
MarketWatch reports that the Wegovy pill continues to dominate the GLP-1 market, remaining a top choice for weight loss despite competition from Eli Lilly’s Foundayo. This indicates ongoing consumer preference and market leadership.
Coverage timeline — 1 article
MarketWatch
It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly’s GLP-1 pill.
2026-06-07 23:35 UTC